ACLARIS THERAPEUTICS DL 1 WKN: A1412H ISIN: US00461U1051 Kürzel: ACRS Forum: Aktien Thema: Hauptdiskussion

Ok wenn ich es richtig verstehe ist es super das sie keine Umsatzgeschäfte bis Ende 2020 benötigen um den Betrieb am laufen zu halten. Sie aber im 1.Quartal nen Nettoumsatz von 3,7Mio hatten

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments May 8, 2019 Submitted IND for ATI-450, an oral MK2 inhibitor RHOFADE net sales of $3.7 million for the first quarter of 2019 Management to Host Conference Call at 5:00 PM ET today Financial Highlights: Liquidity and Capital Resources As of March 31, 2019, Aclaris had aggregate cash, cash equivalents and marketable securities of $136.8 million compared to $168.0 million as of December 31, 2018. The $31.2 million decrease during the quarter ended March 31, 2019 included: Net loss of $37.6 million, $0.8 million of net cash used in working capital, and $0.3 millionin property and equipment purchases. These uses were offset by $4.9 million of non-cash stock-based compensation expense and $2.2 million of non-cash depreciation and amortization expense. Aclaris anticipates that its cash, cash equivalents and marketable securities as of March 31, 2019 will be sufficient to fund its operations into the fourth quarter of 2020, without giving effect to any potential new business development transactions or financing activities. http://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-first-quarter-2019-financial

👋👋👋